

Kiran Biotech Launches Reward Crowdfunding Campaign on Indiegogo to Accelerate Development of AvidinOX

A New Hope in the Fight Against Lung Cancer

INDIEGOGO

Explore IndieShop



FUNDING

AvidinOX: A New Hope Against Lung Cancer

Support the first aerosol therapy for inoperable lung cancer and help bring it to patients.



Rita De Santis

Rome, Italy

[Ask a question](#)

€835 EUR

19 backers

0% of €500.000 Flexible Goal

49 days left

PICK YOUR PERK

 SAVE FOR LATER

 SHARE

Rome, Lazio Sep 30, 2025 ([IssueWire.com](https://www.issuewire.com)) - Kiran Biotech, an Italian biotechnology company specialized in innovative therapies for oncology, announces the launch of its reward crowdfunding campaign on Indiegogo to support the development of **AvidinOX**, a groundbreaking therapeutic platform designed to provide new and more effective treatment options for oncological patients affected by conditions for which currently only limited and non-effective therapies are available.

Focus on Lung Cancer Community: a Call to Action

Lung cancer remains the leading cause of cancer-related deaths globally, with patients facing limited treatment options, especially in advanced stages. Recognizing this urgent unmet need, **Kiran Biotech is committed to accelerating the development of innovative solutions** that have the potential to significantly improve patient outcomes.

Through this reward crowdfunding campaign, the company extends an invitation to patients, families, advocates, and members of the wider biotechnology community. By participating, supporters will directly contribute to advancing scientific research and strengthening the hope of better treatments for those impacted by lung cancer.

What is AvidinOX?

AvidinOX is Kiran Biotech's proprietary therapeutic platform that enables the anchoring of biotinylated molecules to tumor tissues. This innovative mechanism enhances the precision of drug delivery, boosting the effectiveness of anticancer agents while reducing systemic toxicity.

The platform has already been validated in a clinical setting by precisely targeting radioactive biotin to inoperable tumor lesions in **17 patients**. In preclinical studies focused on lung cancer, AvidinOX has shown promising results, suggesting the potential to overcome some of the limitations of chemotherapy and current targeted therapies.

Key advantages of AvidinOX include:

- **Targeted delivery** – precise localization in cancer-affected lung tissue.
- **Reduced side effects** – protecting healthy organs from unnecessary damage.
- **Versatility** – compatibility with multiple therapeutic agents and treatment strategies.

Why Reward Crowdfunding?

Biotech development is both costly and complex, often stalling between laboratory breakthroughs and clinical application. With this reward crowdfunding campaign, Kiran Biotech seeks not only to raise essential funding but also to foster engagement from a global community of supporters.

Unlike equity crowdfunding, this initiative is structured as a **free donation** and does not involve the sale or acquisition of shares, obligations, or credit titles towards Kiran Biotech and/or its directors, employees, and shareholders. Supporters will instead receive **exclusive rewards (perks)** in recognition of their contribution, such as:

- Official acknowledgment as a campaign supporter.
- Access to scientific updates and behind-the-scenes insights.
- Personalized digital materials to share the mission.
- Special mentions for higher contribution tiers.

This model makes participation accessible to everyone who wants to stand alongside scientists and patients in the fight against cancer. Depending on the campaign's success, Kiran Biotech is also evaluating future financing initiatives — including the possibility of equity crowdfunding through authorized platforms — as a next step to further accelerate clinical development.

Funding Goals and Use of Proceeds

Funds raised through Indiegogo will be allocated to:

- **Preclinical validation** – strengthening the scientific evidence supporting AvidinOX.
- **Regulatory preparation** – completing requirements for upcoming clinical trials.
- **Clinical trial design** – advancing first-phase studies in lung cancer patients.
- **Manufacturing scale-up** – optimizing production processes for future needs.

A Call to Action: Join the Mission

The campaign is now live: [AvidinOX: A New Hope Against Lung Cancer](#)

By participating, supporters will not only help advance a high-potential biotech project but also join a mission that could make a lasting difference for thousands of patients and families worldwide.

About Kiran Biotech

Kiran Biotech is a biotechnology company based in Rome, Italy, founded by a team of researchers and professionals with extensive expertise in molecular biology, oncology, and pharmaceutical development. Its mission is to translate scientific discoveries into innovative therapies, with a focus on cancer and other unmet medical needs.

The team combines scientific excellence, entrepreneurial vision, and strong collaborations with universities, research centers, and clinical partners to ensure discoveries can move from the lab to real patient benefit.

Media Contact

Kiran Biotech Srl

Email: kiran@kiranbiotech.com

Phone: +39 334 681 7267

Website: <https://www.kiranbiotech.com>

Disclaimer

This press release is intended for informational purposes only. Participation in the Indiegogo campaign involves voluntary contributions in exchange for non-financial rewards. It does not represent an investment in securities or equity and does not provide ownership rights in Kiran Biotech. Supporters are advised to carefully review all campaign details on Indiegogo before contributing.



Media Contact

IMISEST

*****@imisest.com

Source : Kiran Biotech SRL

[See on IssueWire](#)